Connect with us

Technology

UniDoc Qualifies to Partner with US S&P500 TelCo

Published

on

— Aim to jointly develop and showcase AI eHealth to TelCo customers

VANCOUVER, BC, Sept. 9, 2024 /PRNewswire/ – UniDoc Health Corp. (CSE: UDOC) (FRA: L7T) (OTCQB: UDOCF) (“UniDoc,” or the “Company”), an innovator in the eHealth sector, is excited to announce that it has been approved for partnership with one of the largest US-based telecommunications companies (“TelCo”). This partnership aims to integrate their communications services with UniDoc’s advanced eHealth platform to deliver a healthcare solution to the TelCo’s global community.

Partnership Intention:

Collaboration: UniDoc and TelCo aim to develop a combination of product offerings to enhancing patient engagement and optimize clinician effectiveness across the healthcare spectrum.

Integrated Services Offering: The partnership aims to deliver a solution combining telehealth services, and advanced network and communication platforms.

AI-Enhanced Healthcare: Leveraging UniDoc’s AI technologies to improve data analysis, and enabling precision and predictive healthcare with faster diagnosis and treatment options.

UniDoc’s CEO, Antonio Baldassarre, remarked, “This approval for partnership marks an exciting first step in our working with TelCo. By combining our eHealth solutions with the TelCo’s communications infrastructure, we are excited to work towards expanding access to patient care in the US. This initiative not only broadens our potential market reach but also underscores our commitment to improving healthcare accessibility through cutting-edge technology.”

The Company plans to leverage the TelCo’s 5G network capabilities to ensure that UniDoc’s eHealth solutions are reliably and securely delivered throughout the TelCo’s network. Secure and reliable communication is critical in UniDoc’s mission to provide seamless healthcare services, especially to underserved populations that lack traditional healthcare infrastructure.

Additionally, the potential integration of TelCo’s existing healthcare platforms with the UniDoc solutions could introduce a new level of personalized care, with the goal making it easier for patients to manage their health proactively. This service enhancement aims to transform patient experiences by providing more timely and targeted interventions, driven by real-time data insights and expert medical oversight.

The approval for partnership is the initial step in the development of the relationship between the TelCo and the Company and there can be no assurance that the approval for partnership will result in the development or joint development of products with the Company and TelCo. Accordingly, readers are cautioned that no agreement with TelCo may result from the partnership or upon terms that are favourable or economic for the Company.

On Behalf of the Board of Directors,

~Antonio Baldassarre~

Antonio Baldassarre
CEO, President & Director
UniDoc Health Corp.

About UniDoc Health Corp. (CSE: UDOC) (FRA: L7T) (OTCQB: UDOCF)
UniDoc is developing an eHealth solution which is being designed as a self-contained remote virtual clinic within a private kiosk for patients to undergo full consultations as if they were present in a physician’s office. eHealth opens the doors to a large segment of the population challenged by access, experience or understanding of online computer technology. It is the Company’s belief that physical accessibility is the key to its business proposition. UniDoc is dedicated to unlocking shareholder value by delivering an excellent product and sophisticated commercial network within an expedited timeframe. The UniDoc team encourages engagement, questions, and interest, so please stay in touch and invite anyone who might be interested in our story to visit our website at www.unidoctor.com and signup to receive the latest information with updates on our activities, events and progress.

Forward-Looking Statements
This news release contains statements and information that, to the extent that they are not historical fact, may constitute “forward-looking information” within the meaning of applicable securities legislation. Forward-looking information may include financial and other projections, as well as statements regarding future plans, objectives, or economic performance, or the assumption underlying any of the foregoing. In some cases, forward-looking statements can be identified by terms such as “may”, “would”, “could”, “will”, “will be”, “likely”, “except”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook”, or the negative thereof or other similar expressions concerning matters that are not historical facts. Examples of such statements include, but are not limited to, statements with respect to the partnership between the Company and TelCo, the features of the distributed care platform to be co-developed with TelCo, that the partnership with TelCo will expand patient care and enhance shareholder value, that the partnership with TelCo will assist the Company in delivering its solutions around the world, and that the Company’s healthcare solutions will be offered to TelCo’s global customers.

Forward-looking information is based on the assumptions, estimates, analysis, and opinions of management made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be incorrect. The material factors and assumptions used to develop the forward-looking information contained in this news release include, but are not limited to, key personnel and qualified employees continuing their involvement with the Company; the Company’s ability to secure additional financing on reasonable terms; the competitive conditions of the industries in which the Company operates; and laws and any amendments thereto applicable to the Company.

Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, including, without limitation, risks relating to the future business plans of the Company; risks that the Company will not be able to retain its key personnel; risks that the Company will not be able to secure financing on reasonable terms or at all; as well as all of the other risks as described in the Company’s annual management discussion and analysis dated July 30, 2024 under the heading “Risks Factors.” Accordingly, readers should not place undue reliance on any such forward-looking information.

Further, any forward-looking information speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information. The Company does not undertake any obligation to update any forward-looking information to reflect information or events after the date on which it is made or to reflect the occurrence of unanticipated events, except as required by law, including securities laws.

The CSE does not accept responsibility for the adequacy or accuracy of this release.

View original content to download multimedia:https://www.prnewswire.com/news-releases/unidoc-qualifies-to-partner-with-us-sp500-telco-302241347.html

SOURCE UniDoc Health Corp.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Connatix and JW Player Merge To Create the Industry’s Largest Video Technology and Monetization Platform

Published

on

By

Advanced offering brings unparalleled monetization and streaming capabilities across CTV and OLV for broadcasters, publishers, and advertisers

NEW YORK, Oct. 9, 2024 /PRNewswire/ — JW Player (JWP), the leading video streaming and data insights platform, today announced it is merging with Connatix, the leading video delivery and monetization solution, forming JWP Connatix. By unifying JWP’s broadcast-level live and on-demand streaming, data, and workflow capabilities with Connatix’s full stack advertising and content technology, JWP Connatix becomes the industry’s most comprehensive independent video technology and monetization platform for broadcasters, publishers, and advertisers.

This merger arrives as the digital video ecosystem is experiencing transformational change. Consumers are increasingly cutting the cord in favor of Connected TV (CTV) and streaming services, leading to rapid shifts in global advertising spend and the emergence of new direct-to-consumer subscription and pay-per-view offerings. In 2024, global CTV ad revenue will surpass $30 billion, while the top ten streaming services alone will support nearly 1 billion subscribers. Given this, publishers, broadcasters, and advertisers must transform their video strategies to meet these evolving viewer expectations and business needs.

“How and where viewers consume video is rapidly changing. As a result, media companies require innovative solutions that allow them to maximize audience engagement and help optimize revenue across disparate monetization models, whether it be advertising, subscriptions or commerce,” said David Kashak, Co-founder and CEO of Connatix. “Together, JWP Connatix fulfills that requirement, by accelerating our companies’ mutual visions to create environments where premium video viewing, powered by best-in-class technology, meets high-quality monetization experiences, enabling media leaders to deliver exceptional results.”

JWP Connatix creates an indispensable partner in this rapidly changing video ecosystem, powering streaming for over 2,000 blue-chip media companies, including 80% of the top 25 Comscore US publishers. As the largest independent global video network across CTV and OLV, the company reaches over 1 billion unique users and delivers 30 billion+ combined video plays and ad impressions every month. Key benefits for customers include: 

Global reach and reliable scale: Streaming 7 billion minutes of VOD and live content to over 1 billion unique users on any screen around the worldHybrid monetization models: Support for subscription, advertising and e-commerce business models, leveraging insights from content and audiences to help maximize revenueUnique insights to optimize outcomes: Leverage AI to combine trillions of contextual, consumption, and monetization data signals to match customers with content and ads, boosting engagementSingle end-to-end platform for OLV and CTV: Streamlined video management platform enabling diverse monetization opportunities across content, commerce, and creative

“By joining forces, JWP Connatix ushers in a new era for digital video. The complementary nature of our  businesses enables us to bring a unique combination of scale, product breadth, and industry expertise to the market,” added Dave Otten, CEO and Co-Founder of JWP. “Perhaps more importantly, we are bringing together two knowledgeable, and dedicated teams, whose skill-sets and values are a perfect match. We could not be more excited about this partnership and look forward to shaping the future of digital video together.”

As part of the transaction, Dave Otten will become CEO of the combined company, while David Kashak will serve as its Chairman. JWP Connatix will be headquartered in New York City with additional offices in London, Cluj-Napoca, Eindhoven, Skopje, and Tel Aviv.

About Connatix

Connatix is a video technology company that powers the world’s stories with effortless and inspiring solutions. Through a proprietary full-stack platform, Connatix helps publishers deliver, monetize, analyze and create video, while providing advertisers with premium video inventory and a collection of data intelligence solutions including Deep Contextual™and predictive audience targeting.  Sitting at the forefront of innovation, Connatix leverages the power of AI to optimize revenue and ensure relevancy, efficiency and scale across campaigns.

Connatix currently works with 350+ publisher groups across thousands of sites and leading brands and agencies. The private equity-backed business has been named an AdExchanger Programmatic Power Player for two consecutive years and included on the Inc. 5000 list of the fastest growing companies for three consecutive years. Founded in 2014, Connatix is headquartered in New York City and continues to expand its global footprint with offices in London, Cluj-Napoca, and Tel Aviv.

About JWP

JW Player (JWP) is a leader in video streaming and player technology, providing broadcasters and publishers with a platform for delivering and monetizing video content across web, OTT, CTV, and FAST platforms. JWP’s technology helps deliver exceptional video experiences, engage audiences, and increase viewing time. Pioneering innovations like HLS streaming, header bidding for video, and contextual content recommendations, JWP offers a comprehensive end-to-end streaming management platform. Founded in 2008, JWP is one of the fastest growing SaaS companies in the world with a vision to power video-driven businesses so they thrive in the digital video economy.  Serving over 2,000 global broadcasters, publishers, and video-driven brands, JWP powers video for over 1 billion users each month and 5 billion minutes of video watched. Headquartered in New York, JWP has offices in London, Eindhoven, and Skopje.

Media Contact
Cassady Nordeen
cassady@purposenorthamerica.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/connatix-and-jw-player-merge-to-create-the-industrys-largest-video-technology-and-monetization-platform-302271377.html

SOURCE Connatix

Continue Reading

Technology

Proteotype Awarded £1.5 Million Grant to Advance Early Cancer Detection with Innovative Enlighten® Test

Published

on

By

CAMBRIDGE, United Kingdom, Oct. 9, 2024 /PRNewswire/ — Proteotype Diagnostics Ltd, in collaboration with the University of Southampton, has been awarded £1.5 million in funding from the National Institute for Health and Care Research (NIHR) and the Office for Life Sciences (OLS). The grant (NIHR207538) will support clinical validation of Proteotype’s novel Enlighten® Multi-Cancer Early Detection test, a revolutionary approach to detecting early-stage cancers by focusing on the body’s response to tumour development.

A Breakthrough in Early Cancer Detection

While many cancer diagnostics rely on tumour-released signals, such as circulating tumour DNA, which is often only detectable once cancer has progressed, Enlighten® takes a different and potentially more powerful approach. It measures the host response to tumour development, tracking changing levels of proteins that occur even in the earliest stages of cancer.

Initial results have been promising. At AACR 2024, Proteotype reported a detection rate of 86% across multiple cancers, with a 0% false-positive rate and strong signals for early-stage cancers. The test now needs to be validated in a larger group of patients, enabling a statistically powered calculation of performance.

Dr. Emma Yates, co-founder and Chief Scientific Officer at Proteotype Diagnostics, said: “When cancer is discovered earlier, patients have more treatment options and better outcomes. Enlighten® is designed to disrupt, detecting cancer as early as the immune system, whilst remaining simple enough yet robust enough to fit existing care pathways and NHS needs.”

Focused on Health Equity

Enlighten® will be trialled in real-world NHS settings with a specific focus on reaching higher-risk, underserved populations. The MODERNISED clinical study, led by Professor Andrew Davies from the University of Southampton Experimental Cancer Medicine Centre, will recruit 1,350 participants across Southern England, targeting cancers with high mortality rates in socio-economically deprived areas, such as colorectal, lung, and pancreatic cancers.

Wesley Sukdao, co-founder and CEO of Proteotype Diagnostics shared: “Growing up in poverty in South Africa, I lost three of my closest family members to cancers detected too late, all before I turned fourteen. To meaningfully impact health inequalities, cutting-edge cancer diagnostics must be both affordable and accessible. My team and I are focused to deliver on this mission.”

Driving Cost-Effective Screening for the NHS

Enlighten® does not require highly expensive, specialised equipment or consumables. Affordable laboratory kits applied to crude patient plasma enable easy scale-up for mass screening. With low data requirements and results within 24-hours of sample measurement, it is well positioned for NHS-wide adoption.

MODERNISED will be accompanied by a Health Economic Evaluation to ensure it delivers clinical benefit and meets NHS financial goals.

A Critical Step Forward

This grant is part of a UK Government commitment of £22.5m to deliver the OLS Cancer Programme. The NIHR i4i-OLS call forms part of this programme. Over the next 24-months, Enlighten® will undergo clinical validation, bringing it closer to regulatory approval and potential integration into NHS cancer screening programs.

Professor Andrew Davies, Chief Investigator (MODERNISED), commented: “Enlighten is innovative, capturing changing levels of proteins released into the bloodstream even in the earliest cancer stages. If Enlighten performs well in MODERNISED, it could mark a step change in early cancer diagnostics.”

About Proteotype Diagnostics Ltd

Proteotype is a pioneering diagnostics company dedicated to the development of advanced multi-cancer early detection and personalised medicine tests that measure the host response to tumour development. By leveraging cutting-edge technologies and comprehensive research, Proteotype aims to revolutionise cancer diagnostics and improve early detection, ultimately enhancing patient outcomes and survival rates.

Media contact: pr@proteotype.com 

Email invest@proteotype.com to partner and bring this test to a clinic near you.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/proteotype-awarded-1-5-million-grant-to-advance-early-cancer-detection-with-innovative-enlighten-test-302271612.html

SOURCE Proteotype Diagnostics

Continue Reading

Technology

DCS Awarded $70.7M Contract to Support Army’s Ground Vehicle Systems Center

Published

on

By

ALEXANDRIA, Va., Oct. 9, 2024 /PRNewswire/ — DCS Corporation is pleased to announce the award of the U.S. Army Combat Capabilities Development Command (DEVCOM) Ground Vehicle Systems Center (GVSC) Ground Vehicle Simulation Lab (GVSL) contract valued at $70.7M.

Under this 5-year contract, DCS will continue to provide technical services to the U.S. Army (DEVCOM) GVSC Immersive Simulation Directorate (GVSC-IS) in Warren, Michigan. GVSC-IS is home to a world-class facility that develops and applies physics-based simulations, simulators, crew station design, and virtual simulation in support of Army ground combat vehicle technology research, development, and maturation. Under this contract, DCS will provide technical services for: Immersive Ground Vehicle Simulation development, integration, and execution; Ride Motion Simulation and Crew Station/Turret Motion Based Simulation; crew station development and integration; and conduct and evaluation of Virtual Experimentation. The technology developed will advance the Army’s ability to evaluate concept and existing vehicle systems mobility, durability, and operations on the move.

“For more than 20 years, DCS has supported GVSC-IS and U.S. Army Tank-Automotive and Armaments Command in conducting motion-based and large-scale experiments at the world-class GVSL modeling and simulation facilities,” commented Bill Protzman, DCS President and COO. “We are excited to continue supporting GVSC-IS and the Warfighter.”

DCS has been a trusted partner of the U.S. Army GVSC and its predecessor organizations for more than 35 years. DCS employee-owners work alongside Government counterparts to further the research, development, acquisition, integration, testing, fielding, and post-fielding operations of manned and unmanned ground vehicles. These Government-contractor teams develop and deliver innovative solutions to support the mission of the Army.

About DCS An employee-owned company, DCS offers advanced technology, engineering, and management solutions to Government agencies in the national security sector. The transformative ideas, commitment to quality, and entrepreneurial spirit that characterize our employee-owners allow us to ensure the success of each customer’s mission and actively contribute to the well-being of the Nation. For more information, please visit: https://www.dcscorp.com

Contact: DCS Media, dcsmedia@dcscorp.com, 571-227-6000

DISTRIBUTION STATEMENT A. Approved for public release; distribution is unlimited. OPSEC9069

View original content to download multimedia:https://www.prnewswire.com/news-releases/dcs-awarded-70-7m-contract-to-support-armys-ground-vehicle-systems-center-302270598.html

SOURCE DCS Corporation

Continue Reading

Trending